These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2005-001709-24 Estudio en fase II, abierto, multicéntrico, prospectivo y aleatorizado, con DTIC o la combinación de Gemcitabina y DTIC en sarcomas de partes blandas avanzados del adulto not-yet-due
Exempt 2007-002176-34 Ensayo clínico de fase I-II, no aleatorizado, multicentrico para evaluar la seguridad y la eficacia de la combinación de sorafenib (BAY 43-9006) e ifosfamida en el tratamiento de pacientes con sarcoma... not-yet-due
Ongoing 2007-005755-42 ENSAYO CLÍNICO FASE II DE TRATAMIENTO NEOADYUVANTE CON IFOSFAMIDA A DOSIS ALTAS Y RADIOTERAPIA CONCOMITANTE EN SARCOMAS DE PARTES BLANDAS E IDENTIFICACION DE MARCADORES PREDICTORES DE RESPUESTA not-yet-due
Ongoing 2008-008922-55 ENSAYO FASE II ALEATORIZADO, ABIERTO, MULTICÉNTRICO Y PROSPECTIVO DE DOXORRUBICINA vs TRABECTEDINA Y DOXORRUBICINA EN PRIMERA LÍNEA DE PACIENTES CON SARCOMA DE PARTES BLANDAS AVANZADOS NO OPERABLES Y/... not-yet-due
Completed, but no date 2009-016027-62 ENSAYO CLÍNICO, FASE II, ABIERTO, NO CONTROLADO, MULTICÉNTRICO Y PROSPECTIVO, DE QUIMIOTERAPIA INTENSIVA, CIRUGÍA Y RADIOTERAPIA EN SARCOMA DE EWING DE NIÑOS Y ADULTOS JÓVENES bad-data
Listed as ongoing, but also has a completion date 2010-023484-17 LOCALIZED HIGH-RISK SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL IN ADULTS: AN INTEGRATING APPROACH COMPRISING STANDARD VS HISTOTYPE-TAILORED NEOADJUVANT CHEMOTHERAPY (ISG-STS 10-01) 2016-05-26 bad-data
Reported results 2012-002745-38 Phase II Clinical Trial of Pazopanib to evaluate the activity and tolerability in patients with advanced and/or metastatic liposarcoma who have relapsed following standard therapies or for whom no sta... 2018-03-02 due-trials
Ongoing 2013-005155-32 A phase 2, single arm, multi center trial evaluating the efficacy of the combination of sirolimus and cyclophosphamide in metastatic or unresectable myxoid liposarcoma and chondrosarcoma. not-yet-due
Ongoing 2013-005456-15 A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients with Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC) not-yet-due
Exempt 2014-001549-26 Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus Radiotherapy in Soft Tissue Sarcoma patients. not-yet-due
Ongoing 2015-001048-12 Phase II, single arm, non-randomized and multicenter clinical trial of regorafenib as a single agent in the first-line setting for patients with metastatic and/or unresectable KIT/PDGFR Wild Type GIST... not-yet-due
Ongoing 2016-002464-14 Phase II trial of nab-paclitaxel for the treatment of desmoid tumors and multiply relapsed/refractory desmoplastic small round cell tumors and Ewing sarcoma not-yet-due
Ongoing 2016-004039-19 Phase II multicenter trial of palbociclib in second line of advanced sarcomas with CDK4 overexpression. not-yet-due
Exempt 2016-004040-10 Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas not-yet-due
Exempt 2017-004761-28 A multicenter, phase Ib/II trial of selinexor in combination with imatinib in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) not-yet-due